Prognostic factors for 90-day outcomes in lung cancer patients: a single centre study in 1000 real-world patients

Lung cancer remains the most lethal form of the disease in the United Kingdom, claiming tens of thousands of lives each year. For decades, doctors have relied on a simple, subjective measure called performance status to decide if a patient is strong enough to undergo treatment. This assessment asks a clinician to judge how well a person can carry out daily activities, ranging from being fully active to being bedridden. While easy to use, this method often misses the hidden vulnerabilities of older patients, such as frailty or a buildup of other health conditions, which can make standard treatments dangerous. In the real world, many patients diagnosed with lung cancer are elderly and carry multiple chronic illnesses, yet they are often treated as if they were the younger, healthier volunteers seen in clinical trials. Understanding who is truly fit for therapy, and who might suffer severe harm from it, is a critical challenge for modern medicine.

A team of researchers at a major cancer centre in the northwest of England set out to solve this problem by looking at nearly one thousand real-world patients. They wanted to see if simple, objective measurements could predict who would struggle with treatment better than the traditional performance status score. The study focused on patients with two main types of lung cancer, non-small cell and small cell, who were referred for their first oncology appointment between late 2021 and early 2023. Crucially, the doctors making the treatment decisions did not know the results of the special assessments the researchers were conducting. This ensured that the treatment plans were made exactly as they would be in normal practice, while the researchers quietly gathered data on frailty, other health conditions, and routine blood test results to see how these factors played out over the following three months.

The researchers measured frailty using a tool called the Geriatric-8, which asks eight questions about a person's health and daily life, and they calculated a comorbidity index based on the patient's medical history. They also looked at standard blood tests, checking levels of albumin, a protein that indicates nutritional health, and other markers like haemoglobin and white blood cell counts. The team followed these patients for ninety days from their first visit, tracking three specific outcomes: whether they could finish their planned cancer treatment, whether they had to be admitted to the hospital unexpectedly, and whether they passed away. This ninety-day window was chosen because modern cancer treatments, such as immunotherapy, can last for months or years, making a thirty-day check-up too short to capture the full picture of early risks.

The results revealed a significant gap between how doctors perceived patient fitness and the reality of their health. Although sixty-one percent of the patients were rated as having a good performance status, meaning they appeared active and healthy, nearly two-thirds of the entire group actually had moderate to severe other health conditions. Among patients aged seventy or older, more than three-quarters showed signs of frailty, yet many were still being considered for aggressive treatments. The study found that age itself was not a predictor of who would do poorly; an eighty-year-old with good health markers fared just as well as a younger patient, while a seventy-year-old with hidden frailty struggled. The strongest warning sign for all negative outcomes was low albumin in the blood. Patients with levels below 3.5 grams per deciliter were far more likely to fail to complete their treatment, be admitted to the hospital, or die within the ninety-day period.

Beyond the blood tests, the study identified several other factors that increased the risk of early harm. These included the stage of the cancer, the patient's performance status score, a specific ratio of white blood cells known as the neutrophil-to-lymphocyte ratio, and signs of poor bone marrow function. Socioeconomic deprivation and gender also played a role, with men and those from more deprived areas facing higher risks. In terms of actual outcomes, the ninety-day period was harsh: twenty-six percent of patients who started systemic anti-cancer therapy could not complete even two cycles of treatment, twenty-six percent required an emergency hospital admission, and nearly fifteen percent died. The data showed that patients receiving the most intensive combination of chemotherapy and radiotherapy faced the highest rates of hospital admission, while those treated with targeted radiation alone had the lowest.

The study also highlighted a breakdown in communication during crises. More than half of the patients who ended up in the emergency room within ninety days had not contacted the oncology triage line beforehand, suggesting that proactive monitoring and clearer pathways for help could prevent many of these admissions. The researchers concluded that relying solely on a doctor's subjective impression of a patient's fitness is insufficient. Instead, integrating simple, objective measures like frailty scores, comorbidity counts, and routine blood tests provides a much clearer picture of who can safely handle treatment. These tools allow doctors to identify high-risk patients early, support them with pre-treatment preparation, and make more informed decisions that prioritize patient safety over rigid adherence to age-based rules. The findings suggest that a ninety-day outcome measured from the first consultation is a reliable and meaningful way to assess the early risks of modern cancer care, offering a path toward more personalized and safer treatment for the diverse population of lung cancer patients.